Compounded Tirzepatide with B6, B12, or Niacinamide: What the Additives Are and What Side Effects They Can Cause

Patients on compounded tirzepatide often notice only after the vial arrives that the label reads "tirzepatide / B6," "tirzepatide / B12," or "tirzepatide / niacinamide." Most gastrointestinal side effects of compounded tirzepatide (nausea, vomiting, constipation, diarrhea, fatigue, early satiety) are produced by tirzepatide itself and would occur with the branded forms Mounjaro and Zepbound as well. A smaller subset of skin, allergic, and pharmacokinetic signals can be additive-driven, and one safety question (the tirzepatide-B12 adduct identified in March 2026) is evolving fast enough that anyone using a B12-containing compound should know about it.

This explainer covers why compounded tirzepatide contains additives at all, what each of the four common additives is, how to tell additive-attributable symptoms from tirzepatide-attributable ones, and what to do if the vial does not match the prescription. If you have already noticed a change you cannot explain, report your compounded GLP-1 adverse events. Voluntary patient and clinician reports are the primary surveillance mechanism for compounded GLP-1 medications, and each report carries disproportionate weight.

If you're researching how to qualify for a B6, B12, or niacinamide formulation, our step-by-step guide to getting prescribed compounded tirzepatide walks the 503A personalization pathway.

Why compounded tirzepatide has additives at all

Compounded tirzepatide is prepared under section 503A of the Federal Food, Drug, and Cosmetic Act. The statute prohibits a 503A pharmacy from regularly compounding a drug that is "essentially a copy" of a commercially available product. Pure tirzepatide alone would be difficult to defend as anything other than a copy of Eli Lilly's Mounjaro and Zepbound. Adding a personalization element, most commonly vitamin B6, vitamin B12, niacinamide, glycine, or a B12 plus folate combination, is the regulatory mechanism that distinguishes the compounded product from the branded one. The full statutory and operational picture sits in the 503A personalized formulation framework.

The compounding itself is governed by United States Pharmacopeia General Chapter <795> for non-sterile preparation and <797> for sterile injectables. These chapters set minimum standards for ingredient identity, beyond-use dating, environmental controls, and personnel competency. They do not set the additive recipe. The choice of B6 versus B12 versus niacinamide is made by the compounding pharmacy, and the same prescription written on different days at different pharmacies can be filled with different additive combinations.

The four most common additives in compounded tirzepatide

The four formulations a patient is most likely to encounter are summarized in the table below. Per-additive detail follows.

Vitamin B6 (pyridoxine)

B6 is added on the rationale that it may attenuate nausea. The relevant safety question is chronic toxicity. Pyridoxine causes a sensory peripheral neuropathy at sustained high oral doses. Reviews of the literature consistently caution against more than 50 mg per day for extended periods, and the European Food Safety Authority sets a tolerable upper intake of 12 mg per day. Australia's Therapeutic Goods Administration recently lowered the maximum permitted daily dose in supplements from 200 mg to 100 mg and now requires a peripheral neuropathy warning above 10 mg. The compounded GLP-1 patient is typically receiving low single-digit milligrams of B6 per weekly injection, well below any of these thresholds. Patients already taking high-dose B6 supplements separately should disclose that to their provider.

Vitamin B12 (cobalamin family)

B12 is added on the rationale that caloric restriction can produce relative B12 deficiency and that supplementation is a low-risk hedge. The classic safety question for B12 is cobalt sensitivity. The cobalamin molecule contains a cobalt atom at its center, and cobalt allergy affects an estimated 1 to 3 percent of the population. Subcutaneous and intramuscular routes carry higher sensitization risk than oral, and long-term repeated dosing is itself a risk factor. Reactions can be IgE-mediated and immediate or delayed by 12 to 72 hours, and most often present as injection-site dermatitis. The UK Medicines and Healthcare products Regulatory Agency advises that patients with known cobalt allergy should be vigilant for sensitivity reactions to either hydroxocobalamin or cyanocobalamin. The emerging tirzepatide-B12 adduct concern is a separate signal treated in its own section below.

Niacinamide (nicotinamide, vitamin B3)

Niacinamide is the additive most patients fear without cause. The fear is the niacin flush: facial redness, burning, and itching minutes after a dose. That reaction is produced by nicotinic acid (the carboxyl form of B3), which activates GPR109A receptors on Langerhans cells and provokes prostaglandin-mediated vasodilation. Niacinamide carries the carboxamide form, does not bind GPR109A in the same way, and does not produce the flush. If a patient on niacinamide-containing compounded tirzepatide reports facial flushing, verify the formulation is in fact niacinamide rather than nicotinic acid before assuming the additive is responsible.

Methylcobalamin + folate combinations

A subset of compounded products combine methylcobalamin (an active B12 form) with methylfolate. The B12 considerations above apply unchanged. Methylfolate at the doses used in injectable supplementation is generally well-tolerated.

An evolving safety signal: the March 2026 Lilly letter and the tirzepatide-B12 adduct preprint

On March 12, 2026, Eli Lilly issued an open letter warning of safety risks specific to compounded tirzepatide formulated with vitamin B12. David Hyman, Lilly's Chief Medical Officer, stated that "adding a reactive substance like vitamin B12 without clinical testing or FDA review introduces additional unknown risks." Lilly reported testing of compounded products marketed under methylcobalamin, hydroxocobalamin, and cyanocobalamin labels and found "significant levels of an impurity produced by a chemical reaction between the two substances," along with bacterial contamination and elevated endotoxin in some samples. Lilly named the same concern for compounded tirzepatide formulated with glycine, pyridoxine, niacinamide, or carnitine, and asked the FDA for a nationwide recall.

Two days earlier, Jordan, Arbogast, Clemens, Huang, and Snyder posted a preprint on medRxiv titled A Novel, Widespread Impurity in Mass-Compounded Tirzepatide/B12 Products: Patient Safety Implications. The authors reported that B12 appears to be covalently or coordinately attached to tirzepatide via a ligand substitution reaction, forming a stable tirzepatide-B12 adduct. The adduct remained intact under denaturing conditions and did not dissociate during electrospray ionization mass spectrometry. The altered structure may affect absorption, distribution, metabolism, and excretion, leading to potentially unpredictable pharmacokinetics. Clinical effects in patients are not yet known.

This is preliminary evidence. The medRxiv preprint has not yet been peer reviewed, and the Lilly testing methodology has not been independently replicated. It is also the first specific, mechanistically described impurity signal in this drug class to reach the literature. Until further data is published, patients on B12-containing compounded tirzepatide should be aware of the signal, watch for unusual changes in pharmacology or side-effect pattern, and report anything unusual via MedWatch.

Distinguishing additive side effects from tirzepatide side effects

Without a controlled comparison, definitive attribution of a single symptom to either tirzepatide or the additive is rarely possible. The honest framing is differential, not diagnostic. As a starting point:

• Almost certainly tirzepatide. Nausea, vomiting, constipation, diarrhea, decreased appetite, early satiety, fatigue, and reflux are the documented side effects of tirzepatide itself and would be expected on branded Mounjaro or Zepbound at equivalent doses.
• Consider an additive contribution. Skin rash or pronounced injection-site dermatitis, particularly if delayed 12 to 72 hours, raises a B12 cobalt-sensitivity differential. Facial flushing within minutes of injection should prompt verification that the formulation is niacinamide (which does not flush) rather than nicotinic acid. Sustained peripheral tingling or numbness in a long-term user with multiple B6 sources should prompt a review of cumulative B6 intake. Unusual changes in efficacy, an unexpected loss or gain of appetite suppression, or pharmacokinetic oddities should be reported through MedWatch in light of the emerging tirzepatide-B12 adduct evidence.

The full recognition framework, including which symptoms cross the threshold from "expected" to "report," is in additive-related symptom recognition. The reason additives are part of why batch-to-batch experience differs is covered in formulation as variability source.

Red flag: the vial does not match the prescription

A separate scenario from "did the additive cause my side effect" is "did I receive the right product at all." A widely cited Trustpilot complaint against Eden Telehealth describes a patient who paid USD 576 expecting tirzepatide and received vials labeled MIC (methionine, inositol, choline) and methylfolate, with the refund denied. MIC is a different lipotropic-injection family unrelated to GLP-1 mechanism. The recognition lesson is the same regardless of how that specific case resolved: vials can be visually checked.

• Read the label aloud against the prescription. The active ingredient and the additive should both match what was ordered.
• Note the color. B12-containing solutions are typically pink to red because of the cobalt chromophore. A clear solution where a B12 product was expected, or a pink solution where a B6 product was expected, is a discrepancy worth pausing on.
• Compare viscosity and clarity to prior fills. Sudden changes in either, in the absence of a notified formulation change, are worth questioning.

If the vial does not match, do not inject. Photograph the label, the vial, and the packaging. Request a written correction from the prescribing provider. File a MedWatch report. If the compounding pharmacy is identified on the label, file a complaint with that state's board of pharmacy. The same record-keeping that allows a patient to verify your pharmacy's formulation disclosures in advance is what allows a discrepancy to be documented after the fact.

Switching pharmacy means switching formulation

Telehealth providers do not always disclose, ahead of time, when they change their compounding pharmacy partner. The patient may notice only that the next vial looks different, smells different, injects with slightly different viscosity, or produces a side-effect pattern that does not match the prior fill. A change of pharmacy partner often means a change of additive recipe and a reset of the side-effect profile.

The pragmatic patient response is a short symptom journal, kept by fill date and lot number, that allows the patient and the prescribing clinician to separate "drug-class adaptation" from "this fill is different." Allow two to three weeks before assigning attribution to a new fill. The same approach to symptom timing across a fill change is described in switching pharmacy resets timeline.

Why branded Mounjaro and Zepbound are the cleanest baseline

FDA-approved Mounjaro and Zepbound are pure tirzepatide formulated with standard pharmaceutical excipients only. They contain no B6, no B12, and no niacinamide. The prescribing information and post-market FAERS dataset for these branded products therefore describes the side-effect profile of tirzepatide alone. For patients who want to rule out additive contribution by definition, branded products are the regulatory-grade comparator. Compounded products add the additive variable on top of the same active.

Five questions to ask your prescribing provider

1. Which exact additives are in this vial, and at what concentration?
2. Why was this formulation chosen for me specifically, rather than a different additive or a branded alternative?
3. What is the lot number on this fill, and have you received any complaints associated with this lot or this pharmacy partner?
4. Are you aware of the March 2026 Eli Lilly open letter and the medRxiv preprint on the tirzepatide-B12 adduct, and what is your clinical position on continuing a B12-containing formulation in light of that evidence?
5. If you switch pharmacy partners, will my formulation change, and how will I be notified before the next fill?

A provider who can answer these questions directly is operating with the kind of pharmacovigilance maturity that the compounded GLP-1 category currently lacks at scale. A provider who cannot answer is itself a data point.

Frequently asked questions

Are the B6, B12, or niacinamide doses in compounded tirzepatide high enough to cause vitamin toxicity?

At the per-injection doses typically used in compounded tirzepatide, no. Chronic peripheral neuropathy from B6 has been reported above 50 mg per day for extended periods, and the European Food Safety Authority sets the tolerable upper intake at 12 mg per day. A weekly compounded injection delivers on the order of milligrams per week, well below either threshold. B12 toxicity is not the relevant concern for the cobalamin family; cobalt sensitivity is. Niacinamide is well-tolerated at the doses used.

Why does my niacinamide-containing tirzepatide not cause flushing?

Niacinamide and nicotinic acid are both forms of vitamin B3, but they differ chemically (niacinamide carries a carboxamide group, nicotinic acid a carboxyl group) and pharmacologically. The flushing reaction associated with "niacin" is produced by nicotinic acid binding GPR109A receptors on Langerhans cells and triggering prostaglandin-mediated vasodilation. Niacinamide does not bind GPR109A in the same way and does not produce the flush.

Is the tirzepatide-B12 impurity Eli Lilly described in March 2026 a confirmed health risk?

It is a credible signal but not yet a confirmed clinical risk. Lilly's open letter described chemical and bacterial impurities found in tested compounded products and asked the FDA for a recall. The medRxiv preprint by Jordan and colleagues (March 10, 2026) describes a stable covalent or coordinate adduct between tirzepatide and B12 that may alter pharmacokinetics. Clinical effects in patients have not been characterized, and the preprint has not been peer reviewed. Patients on B12-containing compounded tirzepatide should be aware of the signal and report anything unusual via MedWatch.

What should I do if my new vial has a different additive than my last fill?

Confirm in writing with the prescribing provider that the formulation has been changed, and ask why. Allow two to three weeks before assigning new symptoms to the additive change, and keep a symptom journal indexed by fill date and lot number. If the formulation differs from what was prescribed (rather than what was previously filled), do not inject and follow the wrong-additive protocol described above.

Does branded Mounjaro or Zepbound contain B12 or B6?

No. The FDA-approved branded forms contain pure tirzepatide formulated with standard pharmaceutical excipients only. They do not contain vitamin B6, vitamin B12, niacinamide, or any of the other additives commonly added to compounded versions.

References

1. Eli Lilly and Company. An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12. March 12, 2026. https://investor.lilly.com/news-releases/news-release-details/open-letter-eli-lilly-and-company-warning-potential-patient
2. Jordan B, Arbogast L, Clemens M, Huang L, Snyder M. A Novel, Widespread Impurity in Mass-Compounded Tirzepatide/B12 Products: Patient Safety Implications. medRxiv preprint, March 10, 2026. doi: 10.64898/2026.03.09.26347818v1. https://www.medrxiv.org/content/10.64898/2026.03.09.26347818v1
3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
4. United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations and <797> Pharmaceutical Compounding - Sterile Preparations. https://www.usp.org/compounding
5. Therapeutic Goods Administration (Australia). Peripheral neuropathy with supplementary vitamin B6 (pyridoxine). https://www.tga.gov.au/news/safety-updates/peripheral-neuropathy-supplementary-vitamin-b6-pyridoxine
6. UK Medicines and Healthcare products Regulatory Agency. Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions. https://www.gov.uk/drug-safety-update/vitamin-b12-hydroxocobalamin-cyanocobalamin-advise-patients-with-known-cobalt-allergy-to-be-vigilant-for-sensitivity-reactions
7. Vrolijk MF, Opperhuizen A, Jansen EHJM, et al. Vitamin B-6-Induced Neuropathy: Exploring the Mechanisms of Pyridoxine Toxicity. Adv Nutr. https://pmc.ncbi.nlm.nih.gov/articles/PMC8483950/